Clustering data with hclust algorithm for (Study ST000686)

(Analysis AN001058)
MetaboliteStructureF1F2F3F4
PI 40:4; [M-H]-@6.31ME1915461.991.040.800.64
FFA(24:3)ME1914490.580.601.381.10
PC 32:2; [M-Ac-H]-@5.80ME1914730.840.881.420.80
lysoPE 20:3; [M-H]-@1.63ME1915541.440.740.731.12
lysoPE 22:5; [M-H]-@1.53ME1915571.450.610.871.07
PE 32:1; [M-H]-@6.27ME1915041.170.541.300.90
PA 38:4; [M-H]-@7.02ME1914660.630.981.001.19
N-(eicosanoyl)-sphing-4-enine; [M-H]-@7.96ME1914530.700.751.051.24
plasmenyl-PE 34:3; [M-H]-@6.54ME1915630.760.750.971.27
plasmenyl-PE 42:6; [M-H]-@7.82ME1915781.151.070.681.15
PG 38:4; [M-H]-@6.06ME1915351.251.260.720.97
PA 36:4; [M-H]-@6.29ME1914641.191.100.880.94
PE 32:0; [M-H]-@6.80ME1915031.221.190.920.86
lysoPE 22:4; [M-H]-@1.93ME1915560.831.110.911.10
PC 38:0; [M-Ac-H]-@8.18ME1914900.841.230.990.97
PG 33:0; [M-H]-@6.07ME1915291.051.150.940.95
PC 41:6; [M-Ac-H]-@7.09ME1915021.031.071.060.91
CerP 34:2; [M-H]-@5.45ME1914311.081.021.030.93
PA 35:1; [M-H]-@6.95ME1914601.071.070.990.93
PI 40:6; [M-H]-@5.80ME1915481.041.221.040.84
plasmenyl-PE 38:3; [M-H]-@7.59ME1915700.911.191.090.88
PG 35:0; [M-H]-@6.61ME1915310.771.151.150.93
plasmenyl-PE 38:1; [M-H]-@8.28ME1915680.961.071.220.81
PC 40:7; [M-Ac-H]-@6.37ME1915011.241.091.050.79
lysoPE 20:2; [M-H]-@2.09ME1915531.200.921.140.82
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.45ME1914501.170.971.080.87
plasmenyl-PE 40:6; [M-H]-@7.25ME1915761.350.970.880.94
CL 76:5; [M-2H](2-)@7.09ME1914281.280.870.920.99
lysoPE 16:0; [M-H]-@1.72ME1915491.300.930.920.95
PE 35:1; [M-H]-@6.61ME1915101.360.921.030.83
PC 37:2; [M-Ac-H]-@7.37ME1914881.330.831.060.87
PC 37:1; [M-Ac-H]-@7.83ME1914871.280.821.090.88
PE 38:3; [M-H]-@6.70ME1915201.300.791.110.87
PE 40:8; [M-H]-@5.98ME1915281.390.860.960.91
CerP 32:1; [M-H]-@5.21ME1914291.310.781.000.95
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.44ME1914551.280.781.020.95
PE 35:0; [M-H]-@7.66ME1915091.290.820.980.96
plasmenyl-PE 36:5; [M-H]-@6.37ME1915671.330.830.980.93
FFA(22:3)ME1914450.970.571.231.04
PC 33:2; [M-Ac-H]-@6.15ME1914740.930.671.151.08
PE 35:4; [M-H]-@6.11ME1915120.940.721.101.09
plasmenyl-PE 36:1; [M-H]-@7.76ME1915650.920.691.111.11
PG 34:2; [M-H]-@5.34ME1915301.120.600.891.23
PC 34:4; [M-Ac-H]-@5.75ME1914781.140.680.971.11
lysoPE 18:1; [M-H]-@1.83ME1915511.150.780.931.10
plasmenyl-PE 32:1; [M-H]-@6.64ME1915591.120.780.921.12
FFA(24:1)ME1914471.170.820.931.07
PC 37:4; [M-Ac-H]-@6.68ME1914891.180.800.901.09
lysoPE 18:2; [M-H]-@1.41ME1915521.220.740.961.06
lysoPE 20:4; [M-H]-@1.39ME1915551.250.710.891.11
PG 36:4; [M-H]-@5.43ME1915341.150.711.100.99
plasmenyl-PE 36:4; [M-H]-@6.71ME1915661.160.711.071.01
PC 38:3; [M-Ac-H]-@7.35ME1914931.270.681.100.94
plasmenyl-PE 38:4; [M-H]-@6.96ME1915711.240.661.200.89
plasmenyl-PE 38:6; [M-H]-@6.61ME1915731.200.721.150.92
FFA(18:2)ME1914371.070.801.140.95
FFA(20:1)ME1914391.040.831.150.94
PA 34:3; [M-H]-@6.04ME1914591.040.831.130.96
PE 34:3; [M-H]-@6.06ME1915081.120.861.100.93
PE 36:3; [M-H]-@6.60ME1915151.120.851.080.95
PC 34:3; [M-Ac-H]-@6.00ME1914771.060.861.090.97
FFA(18:1)ME1914361.070.841.100.96
PE 36:1; [M-H]-@7.51ME1915141.090.831.100.96
PC 39:5; [M-Ac-H]-@6.72ME1914981.190.851.030.95
PE 38:1; [M-H]-@7.53ME1915191.200.861.050.93
FFA(20:4) Arachidonic acidME1914411.140.871.020.98
PE 38:5; [M-H]-@6.59ME1915221.140.841.050.97
PI 35:1; [M-H]-@5.91ME1915381.120.811.070.98
FFA(22:2)ME1914441.140.801.210.86
FFA(20:2)ME1914401.050.791.200.92
plasmenyl-PE 40:4; [M-H]-@7.57ME1915741.040.741.160.99
PI 34:2; [M-H]-@5.27ME1915371.000.801.001.10
PI 38:5; [M-H]-@5.40ME1915451.050.820.971.09
FFA(24:0)ME1914461.040.771.001.09
PE 36:5; [M-H]-@5.96ME1915171.050.770.961.12
plasmenyl-PE 32:0; [M-H]-@7.15ME1915581.030.711.031.10
plasmenyl-PE 34:2; [M-H]-@6.79ME1915621.010.761.071.06
plasmenyl-PE 38:5; [M-H]-@6.82ME1915721.030.771.061.05
plasmenyl-PE 38:2; [M-H]-@7.35ME1915690.930.811.091.06
PG 36:2; [M-H]-@6.09ME1915330.950.781.051.10
PI 36:3; [M-H]-@5.39ME1915410.880.821.041.12
FFA(22:1)ME1914430.900.831.071.08
PE 36:4; [M-H]-@6.39ME1915160.910.801.051.10
plasmenyl-PE 36:0; [M-H]-@7.32ME1915640.930.831.041.09
PC 30:1; [M-Ac-H]-@5.60ME1914700.930.820.971.15
CerP 34:1; [M-H]-@5.95ME1914300.930.870.991.11
plasmenyl-PE 34:1; [M-H]-@7.24ME1915610.890.870.991.13
PE 34:1; [M-H]-@6.90ME1915060.840.961.011.10
PI 36:4; [M-H]-@5.24ME1915420.860.931.081.04
plasmenyl-PE 34:0; [M-H]-@7.22ME1915600.890.891.091.03
lysoPE 18:0; [M-H]-@2.48ME1915501.140.940.861.07
PA 38:6; [M-H]-@6.27ME1914681.070.930.891.09
PE 40:2; [M-H]-@7.53ME1915241.141.010.930.98
PE 40:5; [M-H]-@7.12ME1915251.160.980.911.01
PC 35:1; [M-Ac-H]-@7.23ME1914801.041.010.941.03
PE 40:7; [M-H]-@6.47ME1915271.101.010.911.02
PA 40:6; [M-H]-@6.51ME1914691.080.970.951.01
PC 40:6; [M-Ac-H]-@6.82ME1915001.090.970.931.03
PC 34:2; [M-Ac-H]-@6.42ME1914760.960.921.011.06
PA 34:1; [M-H]-@6.87ME1914570.980.921.021.03
PE 38:6; [M-H]-@6.18ME1915230.960.941.021.04
PA 34:2; [M-H]-@6.46ME1914580.930.941.031.05
PG 36:0; [M-H]-@6.89ME1915320.920.971.031.03
PA 36:3; [M-H]-@6.50ME1914631.010.861.021.05
PE 35:2; [M-H]-@6.73ME1915111.010.851.041.04
FFA(22:0)ME1914421.030.901.011.03
PC 36:4; [M-Ac-H]-@6.30ME1914851.020.891.021.03
N-(dodecanoyl)-sphing-4-enine; [M-H]-@5.51ME1914520.990.891.041.03
PA 36:2; [M-H]-@6.89ME1914621.010.911.041.01
PE 36:0; [M-H]-@7.93ME1915131.010.901.031.02
FFA(24:2)ME1914481.040.960.961.04
CerP 41:1; [M-H]-@8.23ME1914331.000.930.981.05
PC 36:1; [M-Ac-H]-@7.55ME1914821.050.910.991.03
PC 38:5; [M-Ac-H]-@6.56ME1914951.030.920.981.04
PE 33:1; [M-H]-@6.63ME1915051.130.971.010.95
PI 38:3; [M-H]-@6.09ME1915431.140.931.020.95
PC 36:2; [M-Ac-H]-@7.02ME1914831.060.881.021.02
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.85ME1914541.060.871.001.03
PC 35:2; [M-Ac-H]-@6.74ME1914811.080.881.001.02
PC 40:5; [M-Ac-H]-@7.02ME1914991.090.911.001.01
PA 38:5; [M-H]-@6.51ME1914671.100.890.981.02
PC 38:4; [M-Ac-H]-@6.96ME1914941.090.910.971.03
PC 38:7; [M-Ac-H]-@5.60ME1914971.130.920.980.99
PE 34:2; [M-H]-@6.49ME1915071.130.930.990.98
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.94ME1914561.140.910.951.01
PC 38:6; [M-Ac-H]-@6.21ME1914961.110.920.951.02
plasmenyl-PE 40:5; [M-H]-@7.41ME1915751.050.961.040.96
FFA(20:0)ME1914381.050.951.020.99
PA 36:1; [M-H]-@7.52ME1914611.050.970.990.99
PC 36:3; [M-Ac-H]-@6.60ME1914841.060.851.051.01
PC 35:0; [M-Ac-H]-@7.73ME1914791.100.901.030.98
PC 38:1; [M-Ac-H]-@7.67ME1914911.090.931.040.96
FFA(16:0)ME1914341.050.901.070.97
PA 36:5; [M-H]-@5.99ME1914651.050.881.060.98
FFA(18:0)ME1914351.050.921.040.98
PC 32:0; [M-Ac-H]-@6.83ME1914711.040.911.031.00
CerP 35:1; [M-H]-@6.29ME1914321.001.020.841.11
PE 37:4; [M-H]-@6.71ME1915181.010.940.831.16
PC 36:5; [M-Ac-H]-@5.93ME1914861.010.900.941.09
PI 36:1; [M-H]-@6.24ME1915391.000.890.931.11
PE 40:6; [M-H]-@6.95ME1915260.900.950.911.15
PE 38:4; [M-H]-@7.05ME1915210.930.940.931.12
PI 34:1; [M-H]-@5.70ME1915360.940.930.961.10
PI 38:4; [M-H]-@5.90ME1915440.981.010.931.07
PI 40:5; [M-H]-@5.95ME1915471.020.990.911.07
PC 34:1; [M-Ac-H]-@6.88ME1914750.950.980.991.05
CL 72:3; [M-2H](2-)@6.91ME1914270.970.950.941.09
PI 36:2; [M-H]-@5.89ME1915400.980.960.961.06
N-(docosanoyl)-sphing-4-enine; [M-H]-@8.46ME1914511.010.840.901.16
PC 32:1; [M-Ac-H]-@6.36ME1914721.070.820.891.14
PC 38:2; [M-Ac-H]-@7.73ME1914920.930.880.881.19
plasmenyl-PE 42:5; [M-H]-@7.94ME1915770.920.850.841.24

Factors:

F1BPA_DOSE:Control
F2BPA_DOSE:High
F3BPA_DOSE:Low
F4BPA_DOSE:Medium
Data matrix
  logo